News

  1. Phase III Trial Of Novartis Drug Afinitor Met Primary Endpoint Of Reducing SEGA Tumor Size In Patients With Tuberous Sclerosis 7/15/2011
    Novartis announced recently Phase III trial results that showed more than one-third of patients taking Afinitor (everolimus) tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC).
  2. INC Research Completes Acquisition Of Kendle International 7/14/2011
    INC Research, LLC, a therapeutically focused contract research organization (CRO) privately held by Avista Capital Partners and Ontario Teachers’ Pension Plan, recently announced it has completed the acquisition of Kendle International Inc.
  3. Novartis Drug Afinitor Met Primary Endpoint Of Phase III Study In Women With Advanced Breast Cancer 7/8/2011
    Novartis announced recently that an interim analysis of a pivotal Phase III study showed Afinitor (everolimus) tablets in combination with exemestane significantly extended progression-free survival (PFS), or time without tumor growth, when compared to placebo plus exemestane in women with advanced breast cancer.
  4. Data From Clinical Studies Of BioTheranostics' CancerTYPE ID® And Breast Cancer Index(SM) Molecular Diagnostic Tests Presented At ASCO 2011 Annual Meeting 6/7/2011
    bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID®, and Breast Cancer Index(SM).
  5. Investment In Oncology Drug Development Remains Strong As 133 Companies Initiate Late-Stage Clinical Trials Representing A 21% Increase 6/6/2011
    Citeline, the world's leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the oncology therapeutic area to uncover trends and patterns in drug development.
  6. Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells As Potential Biomarker For Metastatic Prostate Cancer Clinical Trials 6/4/2011
    Data presented at the 47th American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potential of circulating tumor cells (CTC) as a biomarker for metastatic prostate cancer clinical trials.